The use of endothelial progenitor cells for prevascularized bone tissue engineering

Jeroen Rouwkema, Peter E. Westerweel, Jan de Boer, Marianne C. Verhaar, Clemens van Blitterswijk

Research output: Contribution to journalArticleAcademicpeer-review

77 Citations (Scopus)

Abstract

In vitro vascularization is an upcoming strategy to solve the problem of insufficient blood supply after implantation. Although recent publications show promising results, these studies were generally performed with clinically irrelevant endothelial cell model systems. We tested the use of endothelial progenitor cells (EPC) obtained from umbilical cord blood and human mesenchymal stem cells (hMSC) from the bone marrow for their use in a prevascularized bone tissue engineering setting. MSC were differentiated toward endothelial cells. They formed capillary-like structures containing lumen, stained positive for CD31, attained the ability to take up acetylated low-density lipoproteins, and formed perfused vessels in vivo. However, in a three-dimensional coculture setting with undifferentiated hMSC, the cells stopped expressing CD31 and did not form prevascular structures. EPC from the cord blood were able to form prevascular structures in the same coculture setting, but only when the state of endothelial differentiation was mature. The amount of prevascular structures formed when using EPC was less than when human umbilical vein endothelial cells or human dermal microvascular endothelial cells were used. The degree of organization, however, was higher. We conclude that EPC can be used for complex tissue engineering applications, but the differentiation stage of these cells is important.
Original languageUndefined
Pages (from-to)2015-2027
Number of pages13
JournalTissue engineering. Part A
Volume15
Issue number8
DOIs
Publication statusPublished - 2009

Keywords

  • IR-67180
  • METIS-259093

Cite this

Rouwkema, Jeroen ; Westerweel, Peter E. ; de Boer, Jan ; Verhaar, Marianne C. ; van Blitterswijk, Clemens. / The use of endothelial progenitor cells for prevascularized bone tissue engineering. In: Tissue engineering. Part A. 2009 ; Vol. 15, No. 8. pp. 2015-2027.
@article{5f08e8089464441e852090a813922d6a,
title = "The use of endothelial progenitor cells for prevascularized bone tissue engineering",
abstract = "In vitro vascularization is an upcoming strategy to solve the problem of insufficient blood supply after implantation. Although recent publications show promising results, these studies were generally performed with clinically irrelevant endothelial cell model systems. We tested the use of endothelial progenitor cells (EPC) obtained from umbilical cord blood and human mesenchymal stem cells (hMSC) from the bone marrow for their use in a prevascularized bone tissue engineering setting. MSC were differentiated toward endothelial cells. They formed capillary-like structures containing lumen, stained positive for CD31, attained the ability to take up acetylated low-density lipoproteins, and formed perfused vessels in vivo. However, in a three-dimensional coculture setting with undifferentiated hMSC, the cells stopped expressing CD31 and did not form prevascular structures. EPC from the cord blood were able to form prevascular structures in the same coculture setting, but only when the state of endothelial differentiation was mature. The amount of prevascular structures formed when using EPC was less than when human umbilical vein endothelial cells or human dermal microvascular endothelial cells were used. The degree of organization, however, was higher. We conclude that EPC can be used for complex tissue engineering applications, but the differentiation stage of these cells is important.",
keywords = "IR-67180, METIS-259093",
author = "Jeroen Rouwkema and Westerweel, {Peter E.} and {de Boer}, Jan and Verhaar, {Marianne C.} and {van Blitterswijk}, Clemens",
year = "2009",
doi = "10.1089/ten.tea.2008.0318",
language = "Undefined",
volume = "15",
pages = "2015--2027",
journal = "Tissue engineering. Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

The use of endothelial progenitor cells for prevascularized bone tissue engineering. / Rouwkema, Jeroen; Westerweel, Peter E.; de Boer, Jan; Verhaar, Marianne C.; van Blitterswijk, Clemens.

In: Tissue engineering. Part A, Vol. 15, No. 8, 2009, p. 2015-2027.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The use of endothelial progenitor cells for prevascularized bone tissue engineering

AU - Rouwkema, Jeroen

AU - Westerweel, Peter E.

AU - de Boer, Jan

AU - Verhaar, Marianne C.

AU - van Blitterswijk, Clemens

PY - 2009

Y1 - 2009

N2 - In vitro vascularization is an upcoming strategy to solve the problem of insufficient blood supply after implantation. Although recent publications show promising results, these studies were generally performed with clinically irrelevant endothelial cell model systems. We tested the use of endothelial progenitor cells (EPC) obtained from umbilical cord blood and human mesenchymal stem cells (hMSC) from the bone marrow for their use in a prevascularized bone tissue engineering setting. MSC were differentiated toward endothelial cells. They formed capillary-like structures containing lumen, stained positive for CD31, attained the ability to take up acetylated low-density lipoproteins, and formed perfused vessels in vivo. However, in a three-dimensional coculture setting with undifferentiated hMSC, the cells stopped expressing CD31 and did not form prevascular structures. EPC from the cord blood were able to form prevascular structures in the same coculture setting, but only when the state of endothelial differentiation was mature. The amount of prevascular structures formed when using EPC was less than when human umbilical vein endothelial cells or human dermal microvascular endothelial cells were used. The degree of organization, however, was higher. We conclude that EPC can be used for complex tissue engineering applications, but the differentiation stage of these cells is important.

AB - In vitro vascularization is an upcoming strategy to solve the problem of insufficient blood supply after implantation. Although recent publications show promising results, these studies were generally performed with clinically irrelevant endothelial cell model systems. We tested the use of endothelial progenitor cells (EPC) obtained from umbilical cord blood and human mesenchymal stem cells (hMSC) from the bone marrow for their use in a prevascularized bone tissue engineering setting. MSC were differentiated toward endothelial cells. They formed capillary-like structures containing lumen, stained positive for CD31, attained the ability to take up acetylated low-density lipoproteins, and formed perfused vessels in vivo. However, in a three-dimensional coculture setting with undifferentiated hMSC, the cells stopped expressing CD31 and did not form prevascular structures. EPC from the cord blood were able to form prevascular structures in the same coculture setting, but only when the state of endothelial differentiation was mature. The amount of prevascular structures formed when using EPC was less than when human umbilical vein endothelial cells or human dermal microvascular endothelial cells were used. The degree of organization, however, was higher. We conclude that EPC can be used for complex tissue engineering applications, but the differentiation stage of these cells is important.

KW - IR-67180

KW - METIS-259093

U2 - 10.1089/ten.tea.2008.0318

DO - 10.1089/ten.tea.2008.0318

M3 - Article

VL - 15

SP - 2015

EP - 2027

JO - Tissue engineering. Part A

JF - Tissue engineering. Part A

SN - 1937-3341

IS - 8

ER -